Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use

April 2003

Allergan is introducing Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use.

Restasis is approved for patients with chronic dry eye disease...also called keratoconjunctivitis sicca.

Chronic dry eye disease is caused by chronic inflammation, aging, or autoimmune disorders such as Sjögren's syndrome.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

which drug to use for the initial treatment of hypertension
Diabetes More type 2 diabetes patients will get a "glitazone" along with insulin
Diabetes Do patients have to use Lantus (insulin glargine) at bedtime?
caffeine might reduce the efficacy of methotrexate for rheumatoid arthritis
Cardiology two new antihypertensives promoted for NIGHTTIME dosing
Cardiology rumor that enteric-coated aspirin doesn't work for preventing cardiovascular disease
Dermatology latest treatments for rosacea
Ophthalmology Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use
Women's Health Today Sponge will finally come back
Natural Medicines anti-aging supplements that appear to contain growth hormone
Renal & Urology Oxytrol, the first PATCH for treating overactive bladder
Renal & Urology alpha-blockers for urinary problems in WOMEN
CDC is promoting their new immunization schedule for ADULTS
new HIV drug, Fuzeon (enfuvirtide)
Gastroenterology a new formulation of Kaopectate that is creating confusion
Practice deadly pneumonia that's spreading to North America